79 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
.
Centerview assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory … or responsibility to update, revise or reaffirm its opinion based on circumstances, developments or events occurring after the date of Centerview
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
is untrue. However, neither Lilly nor Purchaser assumes any responsibility for the accuracy or completeness of the information concerning POINT, whether … no responsibility for, and can provide no assurance as to the reliability of, any information that others may give. No broker, dealer, commercial bank
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
, with responsibility for granting any license, registrations or approvals with respect to the Company Products.
“Regulatory Authorizations” means any
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
, with responsibility for granting any license, registrations or approvals with respect to the Company Products.
“Regulatory Authorizations” means any
ARS
ch1 p79ww69gxcs10
1 May 23
Annual report to shareholders
1:52pm
424B3
pep2xh8
11 Jul 22
Prospectus supplement
4:32pm
POS AM
aqov9203v3y fbk
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
EX-4.7
9p0s1ne
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.6
hy6dzsscuivk11xfe
1 Jul 22
Shelf registration
4:13pm
S-3
EX-1.2
swyhubve6suw4
1 Jul 22
Shelf registration
4:13pm